T. Rowe Price Associates
BMY.RT

T. Rowe Price Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

T. Rowe Price Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,063,106
Closed -$4.18M – 2904
2020
Q4 		$4.18M Buy
6,063,106
+1,764,386
+41% +$3.76M ﹤0.01% 1468
2020
Q3 		$9.67M Buy
4,298,720
+591,511
+16% +$1.69M ﹤0.01% 1308
2020
Q2 		$13.3M Sell
3,707,209
-92,536
-2% -$334K ﹤0.01% 1241
2020
Q1 		$14.4M Sell
3,799,745
-201,100
-5% -$662K ﹤0.01% 1160
2019
Q4 		$12M Buy
+4,000,845
New +$10.4M ﹤0.01% 1282

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

T. Rowe Price Associates's BMY.RT Position: Q1 2021 in Review

T. Rowe Price Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 6,063,106 shares — an estimated $4.18M sold.

T. Rowe Price Associates first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $14.4M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • T. Rowe Price Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 6,063,106 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $4.18M.
  • T. Rowe Price Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • T. Rowe Price Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $14.4M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.